Penumbra price target raised to $222 from $205 at RBC Capital

In This Article:

https://www.tipranks.com/news/company-announcements/inhibikase-therapeutics-secures-funding-and-strengthens-leadership

RBC Capital analyst Shagun Singh raised the firm’s price target on Penumbra to $222 from $205 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results. The firm’s industry checks suggest that Q3 underlying utilization trends were positive despite typical summer seasonality driving a sequential step-down in elective procedures, the analyst tells investors in a research note. Investor sentiment is also positive for MedTech stocks going into the earnings season, and investors are likely to continue to chase winners and catalyst-driven names into year-end, RBC added.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on PEN: